These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8788432)

  • 1. Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors.
    McLaughlin JP; Nowak D; Sebastian A; Schultz AG; Archer S; Bidlack JM
    Eur J Pharmacol; 1995 Dec; 294(1):201-6. PubMed ID: 8788432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 14 beta-Chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists.
    McLaughlin JP; Sebastian A; Archer S; Bidlack JM
    Eur J Pharmacol; 1997 Feb; 320(2-3):121-9. PubMed ID: 9059844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
    McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
    Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists.
    Jiang Q; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1107-13. PubMed ID: 7511163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
    Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
    Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delta but not mu-opioid receptors in the spinal cord are involved in antinociception induced by beta-endorphin given intracerebroventricularly in mice.
    Suh HH; Tseng LF
    J Pharmacol Exp Ther; 1990 Jun; 253(3):981-6. PubMed ID: 2162954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors.
    Wong CS; Cherng CH; Luk HN; Ho ST; Tung CS
    Eur J Pharmacol; 1996 Feb; 297(1-2):27-33. PubMed ID: 8851162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse.
    Ohsawa M; Mizoguchi H; Narita M; Chu M; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1106-11. PubMed ID: 10945866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception.
    Rady JJ; Roerig SC; Fujimoto JM
    J Pharmacol Exp Ther; 1991 Feb; 256(2):448-57. PubMed ID: 1847196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
    Tseng LF; Collins KA
    J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
    Negri L; Improta G; Lattanzi R; Potenza RL; Luchetti F; Melchiorri P
    Br J Pharmacol; 1995 Dec; 116(7):2931-8. PubMed ID: 8680727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal delta 2-, but not delta 1-, mu-, or kappa-opioid receptors are involved in the tail-flick inhibition induced by beta-endorphin from nucleus raphe obscurus in the pentobarbital-anesthetized rat.
    Tseng LF; Tsai JH; Collins KA; Portoghese PS
    Eur J Pharmacol; 1995 Apr; 277(2-3):251-6. PubMed ID: 7493616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.
    Seki T; Awamura S; Kimura C; Ide S; Sakano K; Minami M; Nagase H; Satoh M
    Eur J Pharmacol; 1999 Jul; 376(1-2):159-67. PubMed ID: 10440101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.